危重型COVID-19患者左心室射血分数随时间变化对临床结局的影响
这项回顾性观察性队列研究合并三个ICU数据源,纳入808例患者、1614次超声心动图检查,以时间变化的LVEF(≤50%、51-70%、>70%)为主要暴露,ICU死亡为结局,采用含时间变化协变量的多变量Cox模型分析。基线时27%患者LVEF≤50%,17%患者LVEF>70%;LVEF异常(aHR 1.174,95%CI 0.901-1.531)或高动力(aHR 1.041,95%CI 0.785-1.379)均未与ICU死亡率独立相关。作者认为LVEF表型在重症COVID-19中的预后价值可能有限,需更敏感的左室功能指标和心肌损伤标志物进一步研究。
要点
- 在危重型COVID-19患者中,基线27%存在LVEF≤50%,17%存在LVEF>70%。
- 经时间变化多变量Cox模型校正右心功能、前向血流及临床特征后,LVEF≤50%与ICU死亡率无独立关联(aHR 1.174,95%CI 0.901-1.531)。
- LVEF>70%的高动力左室表型同样与ICU死亡率无独立关联(aHR 1.041,95%CI 0.785-1.379)。
- LVEF异常在第一次超声检查时最常见(27%),第五次检查时最少见(17%);高动力左室功能随ICU住院时间延长而更频繁,在第四次超声检查时达峰。
- 作者认为LVEF表型在重症COVID-19中的预后价值可能有限,需结合更敏感的左室功能指标和心肌损伤标志物进一步研究。
适用人群与场景
- 纳入三个ICU数据源中808例危重型COVID-19患者,共1614次超声心动图检查。
- 研究场景为ICU,评估ICU住院期间左室收缩功能动态变化与ICU死亡率的关系。
诊断标准与关键阈值
- 左室收缩功能按LVEF分为三类:≤50%(异常)、51-70%(正常)、>70%(高动力)。
研究设计与关键结果
- 研究类型为回顾性观察性队列研究,合并三个ICU数据仓库,纳入808例患者、1614次超声心动图检查。
- 主要暴露为时间变化的LVEF(≤50%、51-70%、>70%),主要结局为ICU死亡率。
- 基线时27%患者LVEF≤50%,17%患者LVEF>70%;LVEF正常者比例随时间增加。
- LVEF≤50%在第一次超声检查时最普遍(27%),第五次检查时最少见(17%);LVEF>70%随ICU住院时间延长更频繁,在第四次超声检查时达峰。
- 多变量Cox模型(含时间变化协变量,校正急性肺源性心脏病、左室流出道速度时间积分及关键临床特征)显示:LVEF≤50%与ICU死亡率无独立关联(aHR 1.174,95%CI 0.901-1.531),LVEF>70%亦无独立关联(aHR 1.041,95%CI 0.785-1.379)。
证据类型、等级与局限
- 证据类型:回顾性观察性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为LVEF表型在重症COVID-19中的预后价值可能有限。
- 作者建议需纳入更敏感的左室功能指标和心肌损伤标志物进一步研究,以描述LVEF未捕捉的细微变化。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Although right ventricular (RV) dysfunction and acute cor pulmonale are associated with adverse outcomes in critically ill patients with COVID-19, the prognostic significance of left ventricular (LV) systolic dysfunction remains insufficiently characterized. In particular, dynamic changes in cardiac function during intensive care has seldom been studied. We therefore investigated the association between time-varying LV systolic function, assessed by LV ejection fraction (LVEF) and intensive care unit (ICU) mortality in patients with COVID-19, taking into account right ventricular function and forward flow.
METHODS: This retrospective observational cohort study combined three ICU data repositories comprising 808 patients with 1614 echocardiographic examinations. Time-varying LV systolic function (LVEF ≤ 50%, 51-70%, >70%) was the primary exposure, and ICU mortality was the outcome. Multivariable Cox models with time-varying covariates, including, acute cor pulmonale, left ventricular outflow tract velocity time integral and key clinical characteristics were used to assess associations between LV systolic function phenotypes and outcome.
RESULTS: At baseline, 27% of patients had abnormal LV systolic function (LVEF ≤ 50%) and 17% had hyperdynamic LV function (LVEF > 70%). The proportion of patients with normal LV systolic function increased over time. Abnormal LV systolic function was most prevalent at the first echocardiographic examination (27%) and least prevalent at the fifth examination (17%), whereas hyperdynamic LV function became more frequent during ICU stay, peaking at the 4th echocardiographic examination. Abnormal (aHR; 1.174, 95% CI: 0.901-1.531) or hyperdynamic (aHR: 1.041, 95% CI: 0.785-1.379) LV systolic dysfunction was not independently associated with ICU mortality.
CONCLUSION: In critically ill patients with COVID-19, LV systolic dysfunction, including both abnormal and hyperdynamic LV phenotypes, were common and dynamic during ICU stay. LV systolic dysfunction was not independently associated with ICU mortality when modelled longitudinally and adjusted for RV dysfunction, forward flow and other clinical covariates. These findings suggest that the prognostic value LVEF phenotypes in severe COVID-19 may be limited. Further studies incorporating more sensitive measures of LV function and biomarkers of myocardial injury may be required to delineate subtle changes not captured by LVEF.
参考来源
- Chew MS, Jansson S, Jozwiak M, et al. The effect of time-varying left ventricular ejection fraction on clinical outcome in critically ill COVID-19 patients. Ann Intensive Care. 2026. PMID: 42894761. doi:10.1016/j.aicoj.2026.100171
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。